ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.07|
|52 Week High||AU$0.04|
|52 Week Low||AU$0.14|
|1 Month Change||-7.90%|
|3 Month Change||66.67%|
|1 Year Change||-30.00%|
|3 Year Change||-68.18%|
|5 Year Change||-85.86%|
|Change since IPO||-98.72%|
Recent News & Updates
Is ResApp Health (ASX:RAP) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|RAP||AU Healthcare Services||AU Market|
Return vs Industry: RAP underperformed the Australian Healthcare Services industry which returned 46.7% over the past year.
Return vs Market: RAP underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: RAP is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: RAP's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease. The company offers ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department, and primary care markets; and SleepCheck, a smartphone application that allows consumers to self-assess the risk of sleep apnoea. Its technology uses sound to diagnose respiratory diseases, including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease, and asthma.
ResApp Health Fundamentals Summary
|RAP fundamental statistics|
Is RAP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RAP income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0079|
|Net Profit Margin||-9,715.18%|
How did RAP perform over the long term?See historical performance and comparison
Is ResApp Health undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate RAP's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate RAP's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: RAP is unprofitable, so we can't compare its PE Ratio to the Global Healthcare Services industry average.
PE vs Market: RAP is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RAP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RAP is overvalued based on its PB Ratio (7.9x) compared to the AU Healthcare Services industry average (3.8x).
How is ResApp Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ResApp Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has ResApp Health performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RAP is currently unprofitable.
Growing Profit Margin: RAP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RAP is unprofitable, and losses have increased over the past 5 years at a rate of 0.5% per year.
Accelerating Growth: Unable to compare RAP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RAP is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (39.5%).
Return on Equity
High ROE: RAP has a negative Return on Equity (-89.09%), as it is currently unprofitable.
How is ResApp Health's financial position?
Financial Position Analysis
Short Term Liabilities: RAP's short term assets (A$7.5M) exceed its short term liabilities (A$1.7M).
Long Term Liabilities: RAP's short term assets (A$7.5M) exceed its long term liabilities (A$120.2K).
Debt to Equity History and Analysis
Debt Level: RAP is debt free.
Reducing Debt: RAP had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RAP has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RAP has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 16% each year.
What is ResApp Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RAP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RAP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RAP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RAP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RAP's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Anthony James Keating, also known as Tony, has been Chief Executive Officer and Managing Director of ResApp Health Limited since July 2, 2015. Dr. Keating served as a Director of Commercial Engagement...
CEO Compensation Analysis
Compensation vs Market: Tony's total compensation ($USD266.07K) is about average for companies of similar size in the Australian market ($USD302.45K).
Compensation vs Earnings: Tony's compensation has been consistent with company performance over the past year.
Experienced Management: RAP's management team is considered experienced (3.5 years average tenure).
Experienced Board: RAP's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.3%.
ResApp Health Limited's employee growth, exchange listings and data sources
- Name: ResApp Health Limited
- Ticker: RAP
- Exchange: ASX
- Founded: 2000
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: AU$60.144m
- Shares outstanding: 859.20m
- Website: https://www.resapphealth.com.au
- ResApp Health Limited
- 100 Creek Street
- Level 12
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/16 07:04|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.